Technology is no longer just supporting healthcare—it’s becoming the treatment itself. Click Therapeutics is pioneering a new era of medicine, where software doesn’t just supplement traditional treatments but serves as a powerful, standalone therapeutic solution. By transforming digital health into prescription-grade medical treatments, the company is proving that software can be as effective as pharmaceuticals in addressing complex conditions.

At the cutting edge of digital therapeutics, Click Therapeutics isn’t simply developing apps—it’s redefining how medicine is delivered and experienced. Click Therapeutics is on a mission to develop, validate, and commercialize software-based medical treatments designed to address unmet patient needs. By leveraging cognitive and neurobehavioral mechanisms, the company’s Digital Therapeutics^™ empower individuals to take control of their health. Rather than simply managing symptoms, these groundbreaking solutions target the underlying mechanisms of disease—thoughts, sensations, emotions, and behaviors—to create lasting change and improve overall well-being.

Guided by a deep commitment to scientific rigor, Click Therapeutics ensures that its digital therapeutics undergo the same rigorous testing as traditional pharmaceuticals. This dedication to clinical validation and regulatory excellence positions the company as a leader in the emerging field of Software as a Medical Device (SaMD), setting new standards for the future of digital medicine.

Revolutionizing Healthcare with Digital Therapeutics

Click Therapeutics is not just developing apps; it is crafting prescription-grade medical treatments that are changing the way physicians and patients approach chronic and complex conditions. Each solution undergoes a rigorous four-step process to ensure safety, efficacy, and widespread adoption.

First, Click Therapeutics develops prescription software applications designed to function as medical devices, either independently or in conjunction with existing pharmacotherapies. Next, these applications undergo clinical validation through randomized controlled trials, ensuring they meet the highest standards of medical safety and effectiveness. Once validated, the company seeks FDA approval, classifying these solutions as medical devices with independent therapeutic claims or as adjuncts to traditional treatments. Finally, Click Therapeutics works to commercialize its therapies, making them accessible through physician prescriptions and insurance reimbursements while continuously improving them through real-world data analysis.

This methodical approach has led to the successful creation of innovative digital therapeutics, including solutions for smoking cessation, migraine prevention, and major depressive disorder.

Clickotine^®: A Digital Revolution in Smoking Cessation

Quitting smoking is one of the most challenging behavioral changes a person can make, but Click Therapeutics has transformed this process with Clickotine^® (CT-101). This prescription digital therapeutic is designed to help users break free from nicotine addiction through a science-backed, comprehensive program.

Clickotine^® employs controlled breathing exercises, personalized messaging, social engagement, and digital diversions to support individuals on their journey to quit smoking. It even integrates medication access and adherence support while leveraging financial incentives to encourage sustained progress.

The results speak for themselves—35.3% of participants achieved 30-day sustained abstinence from smoking, a figure that significantly surpasses traditional smoking cessation methods. Users engage deeply with the program, with an average of over 100 app opens over eight weeks—three to six times higher than any competing smoking cessation app. This level of engagement underscores the effectiveness of Clickotine^® in transforming lives.

CT-132: Redefining Migraine Treatment with Digital Therapy

Migraine sufferers know all too well the debilitating effects of chronic episodes, often disrupting their daily lives. Click Therapeutics is addressing this challenge with CT-132, an investigational prescription digital therapeutic designed for the preventive treatment of episodic migraine.

CT-132 targets brain hypersensitivity and pain signaling, two critical factors in migraine pathology. By delivering a 12-week clinical intervention, this digital therapy helps patients modulate their response to triggers, restoring their ability to function without constant fear of an impending migraine attack.

Clinical trials have shown remarkable outcomes. The ReMMi-D pivotal trial, a fully decentralized, double-blind, randomized controlled study involving 568 participants, demonstrated that CT-132 led to a statistically significant reduction in monthly migraine days. Patients on the therapy experienced an average of 3.04 fewer migraine days per month—a crucial improvement for those battling chronic migraines. Additionally, participants reported reduced migraine-related disability and improved quality of life, with tangible benefits visible as early as four weeks into treatment.

Strategic Collaborations: Expanding the Reach of Digital Medicine

Click Therapeutics is not alone in its mission. The company has forged key partnerships with leading pharmaceutical firms to expand the reach of digital therapeutics.

• Otsuka Pharmaceutical is collaborating with Click Therapeutics to develop prescription digital therapeutics for major depressive disorder.
• Boehringer Ingelheim has expanded its partnership with Click Therapeutics to create digital solutions for schizophrenia.
• Indivior has joined forces with Click Therapeutics to pioneer novel digital therapeutics targeting substance use disorders.
• Magellan Health is working with Click Therapeutics to launch a fully digital, integrated smoking cessation program.

These collaborations reflect the growing recognition of digital therapeutics as a powerful complement to traditional treatments, unlocking new possibilities for patient care.

The Future of Click Therapeutics

As one of the most promising companies in the MedTech landscape, Click Therapeutics is poised to lead the next wave of medical breakthroughs. With a commitment to rigorous clinical validation, regulatory excellence, and patient-centered innovation, the company is proving that digital therapeutics are not just a concept—they are the future of medicine.

At the heart of its mission lies a simple yet profound belief: healthcare should be more than just treatment—it should be transformation. With each new breakthrough, Click Therapeutics is bringing that vision to life, empowering patients with digital tools that change lives.

David B. Klein | CEO

David B. Klein is a seasoned leader in the life sciences industry, bringing over two decades of experience in biotechnology, strategic advisory, and venture financing. As the Chief Executive Officer of Click Therapeutics, he spearheads the development of prescription digital therapeutics, driving innovation at the intersection of technology and medicine.

An advocate for education and knowledge-sharing, Klein has served as guest faculty in the Biotechnology Program at Columbia University, the NYU Stern School of Business, and Columbia Business School. His contributions to academia reflect his commitment to shaping the next generation of biotech entrepreneurs and industry leaders.

“We are committed to advancing digital medicine to make it evidence-based, accessible to patients, and easy to use.”